成人原发性免疫性血小板减少性紫癜新型药物治疗的研究进展  

Research Progress on New Drug Therapy for Primary Immune Thrombocytopenic Purpura in Adults--Review

作　　者：袁永平 杨翔 胡贝妮 朱宏基 陈懿建[2] YUAN Yong-Ping;YANG Xiang;HU Bei-Ni;ZHU Hong-Ji;CHEN Yi-Jian(Gannan Medical College,Ganzhou 341000,Jiangxi Province,China;Department of Hematology,The First Affiliated Hospital of Gannan Medical College,Ganzhou 341000,Jiangxi Province,China)

机构地区：[1]赣南医学院,江西赣州341000 [2]赣南医学院第一附属医院血液科,江西赣州341000

出　　处：《中国实验血液学杂志》2020年第2期677-681,共5页Journal of Experimental Hematology

基　　金：国家自然科学基金(81060047,81160073);江西省自然科学基金(20132BAB205053);江西省卫生厅重大项目基金(20114011);江西省教育厅科技落地计划(KJLD14085)。

摘　　要：免疫性血小板减少症(immune thrombocytopenia,ITP)是一种免疫性疾病,主要表现为血小板计数降低所导致的出血性风险增高。当前已经出现的一线、二线治疗方案尚不能完全缓解或者保持持续缓解ITP。最近研究中的新型治疗药物包括:刺激血小板生成药物、Syk抑制剂、分子靶向类药物等,这些针对疾病进程的关键步骤起到作用,其中,新型的刺激血小板生成药物从作用机制以及临床研究方面具有较为良好的治疗前景,Syk抑制剂药物在治疗血液系统恶性疾病中有着独特的作用,间充质干细胞的移植更是一种新的治疗思路。这些治疗方法有希望提高ITP患者的生活质量。本文就ITP的新型治疗药物最新研究进展作一综述。Immune thrombocytopenia(ITP)is an immune disease characterized by an increased risk of hemorrhagic disease caused by a decrease in platelet count.At present,the first line,second-line treatment can not completely or maintain continuous remission of ITP.New treatments in recent research include stimulating platelet-producing drugs,Syk inhibitors,and molecular-targeted drugs,etc.,which can play a role in key steps of the progression of the disease.Among them,new types of drugs that stimulate thrombopoiesis shows a better therapeutic prospects with a comparative mechanism and clinical research,Syk inhibitors have a unique role in the treatment of malignant diseases in blood system,and the transplantation of mesenchymal stem cells is a new treatment idea.These treatments show the potential to improve the quality of life in patients with ITP.In this review,the latest research progress of new therapeutic drugs for ITP is summarized briefly.

关 键 词：原发性免疫性血小板减少性紫癜 血小板生成素受体激动剂 脾脏酪氨酸激酶 间充质干细胞 

分 类 号：R554.6[医药卫生—血液循环系统疾病] R558.2[医药卫生—内科学]